Durect Corporation Market Cap ($59.31 Million)
Market Cap & Net Worth: Durect Corporation (DRRX)
Durect Corporation market cap. Durect Corporation (NASDAQ:DRRX) has a market capitalization of $59.31 Million ($59.31 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21068 globally and #4756 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Durect Corporation's stock price $1.91 by its total outstanding shares 31054200 (31.05 Million). Also see DRRX cash flow conversion for how efficiently the company converts equity into cash flow.
Durect Corporation Market Cap History (2015–2025)
Durect Corporation market cap history from 2015 to 2025. Data shows change from $686.30 Million to $59.31 Million (-21.54% CAGR). Check DRRX stock price and chart for real-time trading data and today's change.
Index Memberships
Durect Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #597 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2006 of 3165 |
Weight: Durect Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Durect Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Durect Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore DRRX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.47x
Durect Corporation's market cap is 11.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $686.30 Million | $19.12 Million | -$22.66 Million | 35.89x | N/A |
| 2016 | $416.13 Million | $14.03 Million | -$34.51 Million | 29.67x | N/A |
| 2017 | $286.26 Million | $49.17 Million | -$3.69 Million | 5.82x | N/A |
| 2018 | $150.02 Million | $18.56 Million | -$25.32 Million | 8.08x | N/A |
| 2019 | $1.18 Billion | $29.56 Million | -$20.58 Million | 39.92x | N/A |
| 2020 | $642.82 Million | $30.11 Million | -$13.43 Million | 21.35x | N/A |
| 2021 | $306.16 Million | $13.98 Million | -$36.27 Million | 21.90x | N/A |
| 2022 | $107.45 Million | $19.28 Million | -$35.33 Million | 5.57x | N/A |
| 2023 | $18.32 Million | $8.55 Million | -$27.62 Million | 2.14x | N/A |
| 2024 | $23.29 Million | $2.03 Million | -$8.32 Million | 11.47x | N/A |
Competitor Companies of DRRX by Market Capitalization
Companies near Durect Corporation in the global market cap rankings as of November 4, 2026. Also see DRRX total assets for a full breakdown of the balance sheet.
Key companies related to Durect Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Durect Corporation (2015–2025)
Market capitalization of Durect Corporation from 2015 to today. Between 2015 and today, Durect Corporation's market cap moved from $686.30 Million to $ 59.31 Million, with a yearly change of -21.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $59.31 Million | +154.67% |
| 2024 | $23.29 Million | +27.12% |
| 2023 | $18.32 Million | -82.95% |
| 2022 | $107.45 Million | -64.91% |
| 2021 | $306.16 Million | -52.37% |
| 2020 | $642.82 Million | -45.53% |
| 2019 | $1.18 Billion | +686.59% |
| 2018 | $150.02 Million | -47.59% |
| 2017 | $286.26 Million | -31.21% |
| 2016 | $416.13 Million | -39.37% |
| 2015 | $686.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 9th, 2026 the market cap of Durect Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.31 Million USD |
| MoneyControl | $59.31 Million USD |
| MarketWatch | $59.31 Million USD |
| marketcap.company | $59.31 Million USD |
| Reuters | $59.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more